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Abstract 
The imino-phosphine ligands L1 and L2 were prepared via condensation 
reaction of 2-(diphenylphosphino) benzaldehyde with substituted anilines and 
obtained in very good yields. An equimolar reaction of L1 and L2 with either 
PdCl2(cod) or PtCl2(cod) gave new palladium(II) and platinum(II) complexes 1–
4. The compounds were characterized by elemental analysis, IR, 1H and 31P 
NMR spectroscopy. The molecular structures of 2, 3 and 4 were conﬁrmed by X-
ray crystallography. All the three molecular structures crystallized in monoclinic 
C2/c space system. The coordination geometry around the palladium and 
platinum atoms in respective structures exhibited distorted square planar 
geometry at the metal centers. The complexes were evaluated in vitro for their 
cytotoxic activity against human breast (MCF-7) and human colon (HT-29) 
cancer cells, and they exhibited growth inhibitory activities and selectivity that 
were superior to the standard compound cisplatin. 
 
1. Introduction 
Most of the chemistry of imino-phosphine compounds originated from the 
discovery of the ligand 2-(diphenylphosphino)benzaldehyde by Rauchfuss et al. in 
1982 [1]. This compound has since been preferred as a main precursor in the 
preparation of many derivatives of imino-phosphine ligands. Consequently, 
several metal complexes containing imino-phosphine ligands started to emerge in 
the early 1990s [2–4]. Since then, hetero-dentate ligands with hard and soft P–
N donor atoms with interesting properties have been generated and continue to 
attract interest to date [5–8]. Upon coordination to transition metals, the 
hard and soft combination creates asymmetry in the metal orbitals, which 
subsequently regulates the reactivity of a complex bearing these ligands [5]. An 
illustration of this effect is demonstrated by the observed difference in the 
trans-inﬂuence of the phosphorus donor atom compared to either nitrogen or 
oxygen [5]. 
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Despite the preparation of several phosphine based complexes, they remain 
least explored for their potential to inhibit tumor growth. The likely advanced 
reason could be their susceptibility to oxidation, which makes them very difﬁcult 
to handle in air [9]. The few existing reports on antitumor studies  are based on 
phosphine gold(I) complexes [10–13]. For instance, triethylphosphine (2,3,4,6-
tetra-O-acetyl-β-1-D-thiopyranosato-S)gold(I), commonly known as auranoﬁn is 
the ﬁrst phosphine complex that showed signiﬁcant cytotoxicity about two 
decades ago [10]. In the auranoﬁn molecule, the neutral triethylphosphine 
ligand confers membrane permeability while the mono-anionic 
tetraacetylthioglucose is displaced quite rapidly in vivo. The compound was 
proved to possess in vitro cytotoxic potency against melanoma (B16) and leukemia 
(P388) cancer cell lines [10]. Recently, additional in vitro studies have shown 
that auranoﬁn was able to overcome cisplatin resistance in human ovarian cancer 
cells [11]. In particular, it was found that auranoﬁn causes an alteration of the 
redox state of the cell, leading to an increased production of hydrogen peroxide 
and oxidation of the components of the thioredoxin system, therefore creating 
suitable conditions for enhanced apoptosis [11]. Other gold(I) phosphine 
complexes which have also shown great potential to induce apoptosis on tumor 
cell lines include the 1,2-[bis(diphenylphosphino)]ethane gold(I) [12] and 
tetrakis[tris(hydroxyl-methyl)]phosphine gold(I) chloride [13]. The work of 
Bacchi et al. has mechanistically demonstrated that an imino-phosphine ligand 
which forms a 6-membered ring around the metal center stabilizes the complex 
during biological investigations, while the steric bulkiness of the ligand 
manipulates the activity of the complex against cisplatin resistant cells [14]. In 
the context of this background, we report the synthesis and full characterization 
of sterically congested mononuclear imino-phosphine palladium(II) and 
platinum(II) complexes containing substituted aniline. Antitumor activity of these 
complexes has been investigated in vitro against MCF-7 and HT-29 cancer cell lines 
and the results are herein discussed. This work could add up to the current drive 
in the design and development of platinum group metal (PGM) complexes in 
anticancer therapy. 
 
2. Experimental 
2.1. Materials and instrumentation 
All reactions were carried out under nitrogen atmosphere using a dual 
vacuum/nitrogen line and standard Schlenk techniques unless stated otherwise. 
Solvents were dried and puriﬁed by heating at reﬂux under nitrogen in the 
presence of a suitable drying agent. All the re-agents and starting materials were 
purchased from Sigma-Aldrich and were used without any further puriﬁcation. 
The palladium metal pre-cursor PdCl2(cod) (cod = cyclooctadiene) was prepared 
by following literature method [15]. 
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2.2. Synthesis of ligands 
2.2.1 (2-Diphenylphosphino-benzylidene)-2-methylphenylen-amine (L1) 
To a solution of 2-(diphenylphosphino)benzaldehyde (0.279 g, 0.961 mmol) in 
CH2Cl2 (10 ml) in a Schlenk tube was added 2-methylaniline (0.103 g, 0.961 
mmol) dropwise. Anhydrous magnesium sulfate (~0.5 g) was added to the 
Schlenk tube and the reaction was stirred at room temperature for 20 h. The 
resulting yellow mixture was ﬁltered to obtain a yellow solution, which gave 
yellow oil upon evaporation of the solvent. Yield: 0.2990 g (82%); IR (nujol 
cm−1); ν(C_N  imine)  1622,  ν(C_C  phenyl)  1593,  1585,  1505;  ν(P\Ph) 1435; 
1H NMR (200 MHz, CDCl3): δ 8.99 (d, 1H, J = 5.2, \CH_N); 8.27, 6.91–7.67 (m, 
12H, phenyl); 6.46 (t, 6H, J = 7.6, phenyl); 1.27 (s, 3H,CH3); 31P NMR (161.9 Hz, 
CDCl3) δ − 13.96(s); Anal. Calcd for C26H22NP: C, 82.30; H, 5.84; N, 3.69; Found: C, 
82.04; H, 5.93; N, 3.55. 
 
2.2.2 (2-Diphenylphosphino-benzylidene)-2,6-dimethylphenylen-amine 
(L2) 
The ligand was synthesized according to the procedure described for L1 using 2-
(diphenylphosphino)benzaldehyde (0.2752 g, 0.948 mmol) and 2,6-dimethylaniline 
(0.1149 g, 0.948 mmol). Yellow oil was obtained. Yield: 0.2984 g (80%); IR (nujol 
cm−1); ν(C_N imine) 1632, ν(C_C phenyl) 1590, 1562, 1502; ν(P\Ph) 1434; 1H 
NMR (200 MHz, CDCl3): δ 8.88 (d, 1H, J = 5.2, \CH_N); 8.30, 6.88–7.94 (m, 
12H, phenyl); 6.73 (t, 6H, J = 7.4, phenyl); 1.83 (s, 6H,CH3); 31P NMR (161.9 Hz, 
CDCl3) δ −14.00(s); Anal. Calcd for C27H24NP: C, 82.42; H, 6.15; N, 3.56; Found: C, 
82.63; H, 5.98; N, 3.82. 
 
2.3 Synthesis of metal complexes 
2.3.1 Dichloro[(2-diphenylphosphino-benzylidene)-2-methylphenylen-
amine] palladium(II) (1) 
To a suspension of PdCl2(cod) (0.0482 g, 0.169 mmol) in CH2Cl2 (20 ml) was 
added a solution of L1 (0.0635 g, 0.167 mmol) in CH2Cl2 (5 ml). The reaction was 
stirred at room temperature for 6 h, resulting in a yellow solution. The solution 
was concentrated before excess hexane was added to precipitate out a yellow 
solid. The precipitate was ﬁltered, washed with hexane (2 × 5 ml) and dried 
under vacuum. Suitable crystals for X-ray crystallography were grown by slow 
evaporation of CH3CN solution of the complex. [16]. Yield: 0.0697 g (75%); IR 
(nujol cm−1); ν(C_N imine) 1614, ν(C_C phenyl) 1585, 1560, 1502; 1H NMR (200 
MHz, CDCl3): δ 8.67 (s, 1H, \CH_N); 8.20, 6.92–7.96 (m, 12H, phenyl); 5.77 (d, 6H, 
J = 1.8, phenyl); 2.14 (d, 3H, J = 2.2, CH3); 31P NMR (161.9 Hz, CDCl3) δ 30.47(s); 
Anal. Calcd for C26H22Cl2NPPd: C, 56.09; H, 3.98; N, 2.52; Found: C, 55.83; H, 4.22; N, 
2.77. 
 
http://repository.uwc.ac.za
4 
 
2.3.2 Dichloro-[2-diphenylphosphino-benzylidene)-2,6-dimethylphenylen-
amine] palladium(II) (2) 
The compound was synthesized according to the procedure used in 1, using 
PdCl2(cod)  (0.0424 g,  0.149 mmol)  and  L2  (0.0561 g, 0.143 mmol). Suitable 
crystals for X-ray crystallography were grown by  the  slow  diffusion  of  hexane into 
a  solution  of  the complex  in CH2Cl2. Yield: 0.0567 g (72%); IR (nujol cm−1); 
ν(C_N imine) 1610, ν(C_C phenyl) 1586, 1559, 1501; 1H NMR (200 MHz, CDCl3): δ 
8.62 (s, 1H, \CH_N); 8.22, 6.89–7.92 (m, 12H, phenyl); 5.75 (d, 6H, J = 1.6, 
phenyl); 2.15 (d, 6H, J = 2.2, CH3); 31P NMR (161.9 Hz, CDCl3) δ 27.68(s); Anal.  
Calcd  for  C27H24Cl2NPPd:  C,  56.81;  H, 4.24;  N,  2.45; Found: C, 57.01; H, 4.30; N, 
2.29. 
 
2.3.3 Dichloro-[(2-diphenylphosphino-benzylidene)-2-methylphenylen-
amine] platinum(II) (3) 
The compound was synthesized according to the procedure used in 1, using  
PtCl2(cod)  (0.0388 g,  0.131 mmol)  and  L1 (0.0479 g,0.126 mmol). Suitable 
crystals for X-ray crystallography were grown by  the  slow  diffusion  of  hexane  
into  a  solution  of  the  complex in CH2Cl2. Yield: 0.0618 g (76%); IR (nujol cm− 
1); 1607, ν(C_C phenyl) 1588, 1560, 1502; 1H NMR (200 MHz, CDCl3): δ 8.88 (s, 
1H, \CH_N); 8.17, 6.95–7.86 (m, 12H, phenyl); 5.75 (s, 6H, phenyl); 2.14 (d, 
3H, J = 2.4, CH3); 31P  NMR  (161.9 Hz,  CDCl3)  δ 28.41(s); Anal. Calcd for 
C26H22Cl2NPPt: C, 48.38; H, 3.44; N, 2.17; Found: C, 48.26; H, 3.19; N, 2.42.  
 
2.3.4 Dichloro-[2-diphenylphosphino-benzylidene)-2,6-dimethylphenylen-
amine] platinum(II) (4) 
The compound was synthesized according to the procedure used in 1, using 
PtCl2(cod)  (0.0476 g,  0.161 mmol)  and  L2 (0.0609 g, 0.155 mmol).  Suitable  
crystals  for  X-ray  crystallography  were grown by the slow diffusion of hexane 
into a solution of the complex in CH2Cl2.  Yield: 0.0756 g (74%); IR (nujol  cm-
1); 1603, ν(C_C phenyl) 1583, 1561, 1503; 1H NMR (200 MHz, CDCl3): δ 8.87 
(s, 1H, \CH_N); 8.20, 6.76–7.89 (m, 12H, phenyl); 5.74 (s, 6H, phenyl); 2.13 
(d, 6H, J = 2.2, CH3); 31P NMR (161.9 Hz, CDCl3) δ 26.23(s); Anal. Calcd for 
C27H24Cl2NPPt: C, 49.18; H, 3.67; N, 2.12; Found: C, 49.40; H, 3.72; N, 2.33. 
 
2.4 Molecular structures of 2, 3 and 4 
Single crystals of complexes 2, 3 and 4 suitable for X-ray crystallography were grown 
by various crystallization techniques. X-ray diffraction data for the compound was 
collected on a Bruker KAPPA APEX II DUO diffractometer using graphite-
monochromated Mo-Kα radiation (χ = 0.71073 Å). The crystal structures were 
solved by direct methods using SHELX [17] and reﬁned by full-matrix least-
http://repository.uwc.ac.za
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squares methods based on F2  [17] using SHELX [17] and using the graphics 
interface program ORTEP-3 for Windows [18,19]. 
 
2.5 Cytotoxicity determination 
2.5.1 Cell culture 
Cancerous cell lines MCF-7 and HT-29 were cultured in DMEM medium with 
GlutaMAX-1, 10% (v/v) fetal calf serum, and 0.2% (v/v) streptomycin–penicillin. All 
cell culture reagents were supplied by Invitrogen Ltd. All cell lines were maintained 
at 37 °C in an atmosphere of 5% CO2. Cells were plated in 96 well tissue culture plates 
at a cell density of 2.4 × 104 cells per well or in 24 well tissue culture plates at a cell 
density of 1 × 105 cells per well. After 24 h the medium was replaced with medium 
containing the test compounds. 
 
2.5.2 MTT assay 
The 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) 
assay measures the amount of MTT reduction by the mitochondrial 
dehydrogenase based on the ability of live cells to incorporate and bind the 
dye. 
 
 
 
The cells were plated in 96-well tissue plates at a density of 2.4 × 104 cells/ml 
per well. Cells were then treated with various concentrations of the complexes 
(100 to 10 μM) after which they were incubated for 24 h. Triplicate wells were 
established for each concentration. Just 5 h before the elapse of 24 h, 10 μl of 5 
mg/ml MTT solution was added to each well and the plates were further 
incubated for 4 h. At the end of the incubation period, the media was removed 
from each well and replaced with 50 μl of DMSO. The plates were shaken on a 
rotating shaker for 10 min before taking readings at 560 nm using a 
microplate reader. 
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2.5.3. APOPercentage™ apoptosis assay 
This assay helps with detection and quantiﬁcation of apoptosis. Cells were treated for 
24 h with increasing concentrations (6.25–100 μM) of the complexes and 10 μM 
cisplatin (positive control) and incubated for a further 24 h, after which the cells 
were harvested. A minimum of 10,000 cells per sample was acquired and analyzed 
on a FASCan™ (Becton Dickinson) instrument using CELLQuest PRO software 
(BD Biosciences Pharmingen). All the experiments were done in triplicate. 
 
3 Results and discussion 
3.2 Synthesis of ligands and metal complexes 
The imino-phosphine ligands L1 and L2 were prepared via a Schiff base 
condensation reaction of 2-(diphenylphosphino)benzaldehyde with substituted 
anilines (Scheme 1). The ligands were obtained as light brown oil in good yields of 
over 80%. Imino-phosphine compounds are known for their susceptibility to 
oxidation, therefore an oxygen free technique was used to prevent the ligands from 
possible contamination with phosphine oxide. Ligand L1 is reported for the ﬁrst 
time to the best of our knowledge. L2 has been reported by other research 
groups [5,20,21] but it was independently prepared and characterized by us. The 
ligands were reacted with either PdCl2(cod) or PtCl2(cod) to give the 
corresponding new imino-phosphine palladium(II) and platinum(II) complexes 1–
4 (Scheme 1). The complexes were obtained as yellow solids in good yields 
averaging 70% after ﬁltration and evaporation of solvents. 
 
All the compounds were characterized by a combination of elemental analysis, 
IR, 31P and 1H NMR spectroscopy. In the IR spectra of the ligands, imine 
formation was conﬁrmed by strong absorption bands at 1622 and 1632 cm− 1 
for L1 and L2 respectively. These absorption frequencies are consistent with 
those of related imino-phosphine compounds [22–25]. Coordination of the 
ligands was further conﬁrmed by lower absorption bands between 1603 and 
1614 cm− 1, which is a typical characteristic of metal coordinated imines [22–
25]. 
 
In the 1H NMR spectra of the ligands, doublet peaks were observed at 8.99 ppm and 
8.88 ppm for L1 and L2 respectively due to (HC_N), thus conﬁrming a Schiff base 
condensation reaction. The doublet suggests that the imine proton had coupled 
to the phosphorus by pointing towards the phosphorus lone pair [22,25–28]. 
The 31P NMR spectra of the ligands showed an upﬁeld characteristic singlet at 
around − 14.00 ppm for uncoordinated phosphorus [22]. Coordination of the 
ligands was conﬁrmed in the 1H NMR spectra of complexes, which showed 
singlet peaks in the upﬁeld region 8.62–8.88 ppm. 
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This provided evidence for strong coordination of the imine nitrogen to the 
palladium or platinum metal center. These chemical shift values generally 
reﬂect an upﬁeld shift compared to their corresponding ligands, a 
phenomenon which is consistent with co-ordinated imines [29,30]. The 31P 
NMR spectra of the complexes also revealed a downﬁeld shift in the 
phosphorus peak to around 30.00 ppm, conﬁrming coordination of the 
phosphorus to the metal center [25,28]. 
 
3.2. Single crystal X-ray diffraction studies 
The molecular structures of complexes 2, 3 and 4 were determined by X-ray 
diffraction studies to conﬁrm their structures. The molecular structures of the 
complexes are shown in Figs. 1, 2 and 3 respectively. Crystallographic data and 
reﬁnement residuals are summarized in Table 1, while selected bond lengths and 
bond angles are found in Table 2. 
 
The three molecules crystallize in the monoclinic space group C2/c. The palladium 
and platinum atoms are four coordinated via the P and N atoms of the imino-
phosphine ligand and two chloride anions, generating a distorted square planar 
coordination geometry around the metal center. The bond angles 
N(1)\Pd(1)\P(1) (89.14(5)°) and Cl(2)\Pd(1)\Cl(1) (91.039(18)°) in 2, 
N(1)\Pt(1)\P(1) (88.14(13)°) and Cl(2)\Pt(1)\Cl(1) (89.06(5)°) in 3 and 
N(1)\Pt(1)\P(1) (89.25(7)°) and Cl(2)\Pt(1)\Cl(1) (89.38()°) in 4 describe the 
observed distorted square planar geometry, while also indicating some ring 
strain induced by the chelating nature of the bidentate ligand. 
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The Pd(1)\C1(2) bond length of 2.2841(5)Å and Pt(1)\C1(2) bond length of 
2.2891(14)Å are in good agreement with the average Pd\Cl and Pt\Cl bond 
distances respectively for known complexes [31–33]. The average bond lengths 
Pd(1)\N(1) and Pd(1)\P(1) in 2 and Pt(1)\N(1) and Pt(1)\P(1) in 3 and 4 also 
compare well with the literature values [32–35]. There is a detectable trans-
inﬂuence as evidenced in bond lengths Pd(1)\Cl(1) and Pt(1)\Cl(1) trans- to the 
phosphorus atom which are signiﬁcantly longer than their corresponding bond 
lengths trans- to the amine. This reﬂects the stronger trans-inﬂuence of the 
diphenylphosphino group compared to an amine [28]. 
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3.3. Cytotoxicity studies 
The main  aim of  this study was  to evaluate imino-phosphine palladium(II) 
and platinum(II) complexes as possible antitumor agents. The antitumor 
investigation of these complexes was motivated by two reasons: ﬁrstly the 
complexes are bulky, and the steric bulk around the coordinated metal atom has 
been perceived as a perfect strategy to prevent axial approach to the metal atom, 
which would inhibit the formation of a ﬁve-coordinate intermediate that would 
lead to a ligand substitution [36]. The steric hindrance would also permit high 
selectivity to DNA binding [37–39]. Secondly, chelating bidentate ligands have 
been viewed as important in preventing trans-labilization and undesired 
displacement of the ligands by bio-molecules [40]. Furthermore, imino-
phosphine complexes have been less explored for their potential to inhibit 
tumor growth possibly due to their susceptibility to oxidation. 
 
The free imino-phosphine ligand L2 and palladium(II) and platinum(II) 
complexes 1–4 were evaluated for their potential to exert cytotoxicity on highly 
invasive human breast (MCF-7) and human colon (HT-29) tumor cell lines 
using MTT assay with minor modiﬁcations [41–43]. The compounds were ﬁrst 
solubilized in DMSO. The solvent is regarded as highly effective in accelerating 
the rate of chloride displacement from a complex [44]. The results, expressed as 
concentration of the complex required to inhibit tumor cell growth by 50% (IC50) 
are summarized in Table 3. Cytotoxicity of cisplatin was evaluated under the same 
experimental conditions for comparison. The selectivity index (SI), which gives the 
cytotoxicity safety of the complexes was calculated from IC50 values obtained from 
the induced signiﬁcant levels of apoptosis in all the cell lines. The imino-phosphine 
ligand L2 was also evaluated to assess whether free imino-phosphine ligands could 
exert cytotoxicity on cancer cells, and the ligand did not show any appreciable 
activity (IC50 N 100 μM). Therefore, any observed signiﬁcant activity could be 
attributed to the complexes. 
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The imino-phosphine palladium(II) and platinum(II) complexes 1–4 proved to 
possess remarkable antiproliferative activities against MCF-7 and HT-29 cancer 
cell lines compared to the reference drug cisplatin, which returned IC50 values 
around 100 μM. Furthermore, imino-phosphine palladium(II) complexes 
showed superior cytotoxic activities compared to their platinum(II) 
counterparts. For instance, complexes 1 and 2 displayed cytotoxic effectiveness 
that is almost three times that of complexes 3 and 4 against MCF-7 cancer cell 
lines, and this could be attributed to the higher aqueous solubility of 
palladium(II) complexes, which allows them to dissociate readily in solution, 
thereby making them bio-available [45]. 
 
All the complexes generally exhibited higher cytotoxic activities against human colon 
(HT-29) cell line (IC50 29–55 μM) compared to the human breast (MCF-7) cell line. 
However, the highest cytotoxic activity was observed in complex 2 (IC50 = 29 μM), 
which was approximately four times more potent than cisplatin against the two 
examined cancer cell lines. The general pattern observed in cytotoxicity values for 
the complexes across the two cell lines showed higher activities for 2 and 4. These 
complexes contain aniline with two methyl groups substituted at ortho-positions, 
making the complexes more sterically demanding compared to 1 and 3. This trend 
http://repository.uwc.ac.za
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is supported by the literature which stresses the importance of steric congestion in 
preventing axial approach to the coordinated metal atom, thereby permitting high 
selectivity to DNA binding [36–39]. Furthermore, complexes 1 and 2 gave selectivity 
indices N 2 against the two cell lines and their selectivity towards these cancer cell 
lines make them promising compounds. 
 
The imino-phosphine ligands L1 and L2 form a 6-membered ring around the 
metal center, which stabilized the complexes during biological investigations, and 
probably resulting in the observed antitumor proﬁles [14]. The complexes are also 
square planar with metal chloride bonds in cis-position, and when considering the 
proposed mechanism of action of cisplatin [46,47], it is reasonable to suggest that 
cytotoxicity of these imino-phosphine complexes is derived from DNA binding. It is 
also well known that square planar metal complexes with aromatic ligands bind to 
DNA by intercalation, implying that the complexes have potential as intercalation 
agents [48,49]. Our initial study therefore, has shown that imino-phosphine 
complexes are promising antitumor agents. However, further biological 
investigations are needed to elucidate the intercalation modes and study the 
structure–activity relationship of the complexes, especially those that showed 
remarkable cytotoxicity proﬁles in order to qualify them as potential drugs. 
 
APOPercentage was used to evaluate pro-apoptotic activity of the complexes. The 
assay was performed following a literature procedure [50]. In the pro-apoptotic 
activity of the complexes (Figs. 4 and 5), a dose dependent increase in the number 
of apoptotic cells was observed in HT-29 and MCF-7 cell lines treated with the 
complexes, suggesting that the complexes induced apoptosis against the examined 
cell lines. 
 
4. Conclusions 
We have successfully prepared and fully characterized imino-phosphine 
palladium(II) and platinum(II) complexes. The complexes were evaluated for the 
ﬁrst time in vitro for their cytotoxic activity against human breast (MCF-7) and 
human colon (HT-29) cancer cell lines.  
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The free imino-phosphine ligand did not return any appreciable activity against 
the examined cell lines. The complexes exhibited growth inhibitory activities that 
were even better than cisplatin, with the highest cytotoxic activity pronounced in 
complex 2 (IC50 = 29 μM). Complex 2 also displayed remarkable cytotoxicity 
and selectivity against the human breast (MCF-7) cell line (IC50 = 28.5 μM) 
compared to complex 4 (IC50 = 86 μM). 
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